Triple
T20301280
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Brilinta |
E505483
|
entity |
| Predicate | marketedAs |
P1395
|
FINISHED |
| Object | Brilique |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Brilique | Statement: [Brilinta, marketedAs, Brilique]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Brilique Context triple: [Brilinta, marketedAs, Brilique]
-
A.
Atalide
Atalide is a central tragic heroine in Jean Racine’s 1672 play "Bajazet," caught in a complex web of love, jealousy, and political intrigue in the Ottoman court.
-
B.
Docefrez
Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
-
C.
Acomplia
Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
-
D.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Brilique Target entity description: Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
-
A.
Atalide
Atalide is a central tragic heroine in Jean Racine’s 1672 play "Bajazet," caught in a complex web of love, jealousy, and political intrigue in the Ottoman court.
-
B.
Docefrez
Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
-
C.
Acomplia
Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
-
D.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b4b8ab648190906e18538c250148 |
completed | April 16, 2026, 10:06 a.m. |
| NER | Named-entity recognition | batch_69e6770c700c81909da247cef0d0f1eb |
completed | April 20, 2026, 6:57 p.m. |
Created at: April 16, 2026, 11:17 a.m.